SAN DIEGO , Oct. 8, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA ) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal fourth quarter ended June 30, 2024 , and provided a corporate update.
Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, whereby Kayak Mergeco will merge with and into TuHURA with TuHURA surviving the merger and becoming Kintara's direct, wholly-owned subsidiary (the "Merger").
At Kintara's special meeting of stockholders held on October 4, 2024 , Kintara's stockholders approved the requisite proposals to effect the completion of the proposed Merger with TuHURA. The proposed Merger is expected to be consummated in mid-October 2024 , subject to the satisfaction of the remaining closing conditions under the Merger Agreement. As of October 7, 2024 , four patients have been dosed in Kintara's open label 15-patient REM-001 study (the "REM-001 Study") in cutaneous metastatic breast cancer (CMBC).
The majority of the costs to run the REM-001 Study will be covered by the $2.0 million Small Business Innovation Res.
